Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions frequently emphasize the identification of genetic markers linked to drug resistance in multiple myeloma, with contributors describing the work as revolutionary and aiming to personalize treatment. Phrases like "better clinical outcomes for patients" and references to ongoing research efforts contribute to a tone of enthusiasm and urgency, illustrating the importance of this research in the fight against cancer.
The majority of discussions highlight a consensus on the significance of the findings, with many participants expressing strong support for the research outcomes.
Both the excitement and curiosity surrounding the genetic findings indicate a high level of interest in the topic, especially among those directly involved in cancer research.
Posters engage deeply with the content, frequently referencing specific methodologies and implications, which indicates a thorough comprehension and commitment to the subject matter.
Commenters perceive this research as having a substantial positive impact on treatment strategies for multiple myeloma patients, emphasizing its potential to improve clinical outcomes.
Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable clinicians to spot drug resistance and tailor treatment, resulting in better clinical outcomes for patients. Watch now: https://t.co/iwpBem6pIf
Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequent regimen choice in relapsed/refractory myeloma #mmsm https://t.co/0cgB0AcjfM https://t.co/a23w4qPF9C
Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Congratulations to @DrSarahGooding for leading this study. https://t.co/tbXsCHPKlY
Discover more about how researchers at the MRC WIMM are investigating the genetic causes of drug resistant Multiple myeloma in this new animation. https://t.co/ZviBX7FUhV #multiplemyeloma #cancer #dna
Multiple cereblon genetic changes are associated with acquired #resistance to lenalidomide or pomalidomide in #MultipleMyeloma. @DrSarahGooding @NaserAnsariPour @pauladhiman @NBahlis @pvyas_oxford @OxfordBRC @bdi_oxford @MRC_WIMM #IMiD #haematology https://t.co/OCPkKNvX4z https://t.co/dfYs0ubsFk
Research from the @SarahGooding @Chapman_lab_UK has shown that drug resistant multiple myeloma is driven by clonal evolution. Find out more in a new animation. @OxfordHaem @MRC_WIMM https://t.co/piASPRjfGT
Researchers at Oxford University have identified genetic markers common in drug-resistant multiple myeloma. This discovery could help clinicians identify drug resistance early and customize treatment, potentially…
Drug resistance presents a major challenge in treating Multiple Myeloma. Researchers at MRC WIMM have uncovered genetic causes influencing treatment outcomes, helping to personalize therapies and potentially reduce drug…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @MRC_MHU: Research from the @SarahGooding @Chapman_lab_UK has shown that drug resistant multiple myeloma is driven by clonal evolution.…
RT @MRC_WIMM: Discover more about how researchers at the MRC WIMM are investigating the genetic causes of drug resistant Multiple myeloma i…
RT @MRC_WIMM: Discover more about how researchers at the MRC WIMM are investigating the genetic causes of drug resistant Multiple myeloma i…
Discover more about how researchers at the MRC WIMM are investigating the genetic causes of drug resistant Multiple myeloma in this new animation. https://t.co/ZviBX7FUhV #multiplemyeloma #cancer #dna
Research from the @SarahGooding @Chapman_lab_UK has shown that drug resistant multiple myeloma is driven by clonal evolution. Find out more in a new animation. @OxfordHaem @MRC_WIMM https://t.co/piASPRjfGT
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
RT @Sci_Ani: Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable c…
Researchers at Oxford University have identified #genetic markers in #drug-resistant multiple #myeloma. These markers enable clinicians to spot drug resistance and tailor treatment, resulting in better clinical outcomes for patients. Watch now: https://t.co/iwpBem6pIf
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @OxfordHaem: Multiple cereblon genetic changes are associated with acquired #resistance to lenalidomide or pomalidomide in #MultipleMye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @OxfordHaem: Multiple cereblon genetic changes are associated with acquired #resistance to lenalidomide or pomalidomide in #MultipleMye…
Multiple cereblon genetic changes are associated with acquired #resistance to lenalidomide or pomalidomide in #MultipleMyeloma. @DrSarahGooding @NaserAnsariPour @pauladhiman @NBahlis @pvyas_oxford @OxfordBRC @bdi_oxford @MRC_WIMM #IMiD #haematology https://t.co/OCPkKNvX4z https://t.co/dfYs0ubsFk
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @BloodJournal: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple mye…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @Transplant_Doc: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple m…
Cereblon genetic alterations detected using WGS sequencing and RNASeq data in newly diagnosed, lenalidomide refractory & pomalidomide refractory multiple myeloma and association with poorer clinical outcomes #mmsm https://t.co/CUs6JDQn6g https://t.co/G87hV8iiYw
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma @BloodJournal #mmsm #MYELOMA https://t.co/I6K019iDdK
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. https://t.co/QVh48QJVHO
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
New article: Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. https://t.co/ILs7fIXOnJ #MMSM #MultipleMyeloma #hematology https://t.co/e6TzZIHv2L
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
RT @DrSarahGooding: Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequ…
Our paper is out in Blood today! Genetic cereblon changes are frequent at IMiD resistance and could help inform subsequent regimen choice in relapsed/refractory myeloma #mmsm https://t.co/0cgB0AcjfM https://t.co/a23w4qPF9C
RT @NaserAnsariPour: Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Cong…
SRBN point mutations, copy loss/structural variation and a specific variant transcript (exon 10-spliced) associated with inferior responses increase with progressive IMiD exposure in pts with MM, eventually occurring in up to 1/3rd of them: https://t.co/xOqR2SQnCt #MMSM #hemeonc
RT @NaserAnsariPour: Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Cong…
RT @NaserAnsariPour: Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Cong…
RT @NaserAnsariPour: Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Cong…
RT @NaserAnsariPour: Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Cong…
Finding genomic aberrations responsible for relapse/refractory multiple myeloma. Our WGS-based CRBN paper is out! Congratulations to @DrSarahGooding for leading this study. https://t.co/tbXsCHPKlY